Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma

NCT00389285 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: rIL-21 only
DRUG: rIL-21 + sorafenib

Sponsor

ZymoGenetics